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A B S T R A C T
As short tandem repeat markers remain the foundation of human identiﬁcation throughout the world,
new STR multiplexes require rigorous testing to ensure the assays are sufﬁciently robust and reliable for
genotyping purposes. The PowerPlex1 18D System was created for the direct ampliﬁcation of buccal and
blood samples from FTA1 storage cards and reliably accommodates other sample materials. The
PowerPlex1 18D System allows simultaneous ampliﬁcation of the 13 CODIS loci and amelogenin along
with four additional loci: Penta E, Penta D, D2S1338, and D19S433. To demonstrate suitability for human
identiﬁcation testing, the PowerPlex1 18D System was tested for sensitivity, concordance, inhibitor
tolerance, and performance with thermal cycling and reaction condition variation following SWGDAM
developmental validation guidelines. Given these results, PowerPlex1 18D System can conﬁdently be
used for forensic and human identiﬁcation testing.
Published by Elsevier Ireland Ltd.
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To achieve greater efﬁciency, offender databasing laboratories
have sought technology improvements to handle greater through-
put requirements. Automation, megaplex STR assays, and multi-
capillary electrophoresis instruments have become common over
the last decade, allowing signiﬁcant increases in throughput. More
recently, direct ampliﬁcation has become attractive to laboratories* Corresponding author. Tel.: +1 800 356 9526x1207.
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Open access under CC BY-NC-ND license.because it can dramatically shorten processing times for genotyping
laboratories. By removing the DNA puriﬁcation step signiﬁcant
reductions in labor and reagent costs can be realized. Because of its
long-term storage capabilities at room temperature, FTA1paper (GE
Healthcare/Whatman, Waukesha, WI) has been a popular storage
method and material for direct ampliﬁcation. However, chemicals in
the paper intended to lyse cells and stabilize DNA can inhibit PCR and
typically must be removed for successful STR ampliﬁcation. The
PowerPlex1 18D System was developed to address the challenges
associated with direct ampliﬁcation, especially from FTA1 paper,
and furthers efﬁciency through a rapid thermal cycling protocol.
The PowerPlex1 18D System allows analysis of the 13 CODIS
loci and amelogenin along with four additional loci: Penta E, Penta
D, D2S1338, and D19S433. The Penta E and Penta D or D2S1338
and D19S433 loci have been routinely used alongside the 13 CODIS
loci for over ten years as part of the PowerPlex1 16 System
(Promega, Madison, WI) and the AmpF‘STR1 Identiﬁler1 PCR
Ampliﬁcation Kit (Life Technologies/Applied Biosystems, Carlsbad,
CA). Inclusion of all four of these loci increases discrimination as
well as supports data sharing between current databases. The
Table 1
Percentage of complete expected proﬁles observed (complete proﬁles observed/
replicate number) at each extracted DNA quantity.
26 cycles 27 and 28 cycles 30 cycles
50 pg 0% 0% 11%
0.1 ng 0% 0% 83%
0.2 ng 0% 0% 94%
1 ng 100% 100% 100%
5 ng 100% 100% 100%
n= 6 18 18
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blood samples from FTA1 paper, and reliably accommodates other
sample materials. Additionally, the rapid thermal cycling protocol
reduces the cycling time to approximately one and a half hours.
The ﬁve-color system is compatible with the Applied Biosystems
3130 and 3500 Genetic Analyzers, and 3730 DNA Analyzer.
Validation of the PowerPlex1 18D System followed SWGDAM
developmental validation guidelines [1]. Studies were performed
to demonstrate the effectiveness and performance of the Power-
Plex1 18D System for sensitivity, concordance, robustness with
varied thermal cycling and reaction conditions, and resilience
against several contaminating substances. The PowerPlex1 18D
System was demonstrated to be a robust and reliable identiﬁcation
assay ﬁt for human identiﬁcation purposes.
2. Materials, methods, and techniques
2.1. Samples
Testing was performed with buccal FTA1, blood FTA1, and
extracted DNA samples. Buccal FTA1 samples were created from
buccal swabs collected from volunteers or unidentiﬁed offenders
and transferred by contact to Indicating FTA1 paper (GE
Healthcare/Whatman). Blood FTA1 samples were created follow-
ing the product instructions for FTA1 Micro Cards. A 60 ml or
125 ml volume of whole blood anti-coagulated with K2EDTA was
spotted on FTA1 paper. Extracted DNA was puriﬁed from whole
blood by organic extraction, and quantiﬁed using A260 absorbance.
Concordance testing was performed using a total of 418
samples of various types. Samples included FTA1 paper, S&S 903
paper (GE Healthcare/Whatman), Bode Buccal DNA CollectorsTM
(Bode Technologies, Lorton, VA), Omni SwabsTM (GE Healthcare/
Whatman) and extracted DNA. Direct ampliﬁcations were
performed using 1.2 mm disks punched from FTA1 paper and
S&S 903 paper and added directly into reactions or 1.2 mm disks
from Bode Buccal DNA CollectorsTM pretreated with Bode
PunchPrepTM (Bode Technologies). Alternatively, reactions were
performed using 2 ml of an Omni SwabTM extract generated with
prototype SwabSolutionTM (Promega) or 1 ml of extracted DNA.
Species studies were conducted using puriﬁed DNA from higher
primates, domestic animals, and common microorganisms ampli-
ﬁed for 30 cycles. One nanogram was used for primates (privately
obtained collection) and bacteria (ATCC, Manassas, VA), ten
nanograms for domestic animals (Novagen, Madison, WI) (Zyagen,
San Diego, CA), and two nanograms for yeast (ATCC). Species
include: chimpanzee, gorilla, orangutan, cow, dog, chicken, rabbit,
cat, deer, horse, pig, Candida albicans, Saccharomyces cervisae,
Escherichia coli, Streptococcus salivarius, Acinetobacter lwofﬁi,
Streptococcus mutans, Streptococcus mitis, Fusobacterium nucleatum,
Enterococcus faecalis, Lactobacillis acidophilis, Staphylococcus epi-
dermidis, and Micrococcus luteus.
Several common forensic inhibitors were tested including
hematin (Sigma–Aldrich, St. Louis, MO), humic acid (Sigma–
Aldrich), tannic acid (Sigma–Aldrich), chocolate, tobacco, sugar,
and coffee as well as common puriﬁcation contaminants including
EDTA (Sigma–Aldrich), ethanol, and SDS (Fisher Scientiﬁc,
Pittsburgh, PA). No weights were available for the chocolate,
tobacco, or sugar samples.
2.2. Ampliﬁcation methods
Ampliﬁcations were performed on a GeneAmp1 PCR System
9700 (Life Technologies/Applied Biosystems) using commercially
available PowerPlex1 18D reagents. Final reaction volume was
25 ml. Each direct ampliﬁcation used a 1.2 mm diameter punch.
Except where noted, buccal FTA1 reactions used two punches andblood FTA1 reactions used one punch. When amplifying extracted
DNA 5ng was typically used. Negative controls were included in all
experiments, and consisted of reaction reagents only (Supplemen-
tal Fig. 1). The thermal cycling method listed in the manufacturer’s
technical manual [2] was followed, unless speciﬁcally mentioned
otherwise: 96 8C for 2 min, 94 8C for 10 s and 60 8C for 1 min for 27
cycles, a ﬁnal extension at 60 8C for 20 min, and a 4 8C soak.
2.3. Electrophoresis and analysis
Electrophoresis and detection methods followed the manufac-
turer’s technical manual. Samples were prepared for capillary
electrophoresis using 1 ml CC5 ILS 500, 10 ml Hi-DiTM formamide
(Life Technologies/Applied Biosystems), and 1 ml sample or allelic
ladder. Injection conditions for the 3130xl Genetic Analyzer and
3730 DNA Analyzer (Life Technologies/Applied Biosystems)
instruments were 3 kV and 5 s. The 3500xL Genetic Analyzer used
1.2 kV and either 12 or 24 s for injection. Any deviations from these
injection conditions are noted in the results. The analysis utilized a
minimum threshold of 50 RFU for the 3130xl Genetic Analyzer, 175
RFU for the 3500xL Genetic Analyzer, and 150 RFU for the 3730
DNA Analyzer except for the concordance study analysis, which
used individual laboratory guidelines with thresholds ranging
from 50 to 150 RFU. Lastly, a 20% global stutter ﬁlter was applied
for all studies with the exception of the sensitivity and species
studies.
3. Results
3.1. Sensitivity studies
Because the PowerPlex1 18D System can accommodate
puriﬁed template DNA and direct ampliﬁcation materials, sensi-
tivity studies were performed using both extracted DNA and FTA1
materials. Extracted DNA was tested with two DNA dilution series
with ﬁnal amounts of 0.05 ng, 0.1 ng, 0.2 ng, 1 ng, and 5 ng per
reaction. The DNA titrations were characterized at multiple cycle
numbers: 26, 27, 28, and 30 cycles, and analyzed with no global
ﬁlter. Sensitivity was appropriate for a typical direct ampliﬁcation
sample and the lower cycle number listed in the technical manual
(27 cycles), while increased cycle number improved sensitivity.
Complete expected proﬁles (all expected alleles at each locus were
present) were observed with 1 ng extracted DNA using 27 or 28
cycles, and 0.1 ng using 30 cycles (Table 1). Average locus peak
height ratios at 1 ng were 90% (Supplemental Fig. 2). Allelic
imbalances (peak height ratios of <70%) due to stochastic effects
[3–5] were observed with 0.05 ng, 0.1 ng, and occasionally 0.2 ng
of template DNA (Supplemental Table 1).
Sample distribution can be variable across direct ampliﬁcation
materials [6]. In contrast to extracted samples in which the entire
sample is used to create a homogenous extracted solution, direct
ampliﬁcation uses a small portion from a heterogeneous, dispersed
sample. With this distribution, sampling contributes to peak
height variation. Although a single punch contains adequate
material for reliable genotyping, a laboratory may chose to include
Fig. 1. Percentage of completeproﬁles varying buccal or blood FTA1 punch number
and size (buccal FTA1 samples n = 22, blood FTA1 samples n = 11).
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potential failures due to sampling. Varied punch number and size
was evaluated using buccal and blood FTA1 samples to determine
the impact of increased FTA1 amounts on the PowerPlex1 18D
System. Reactions included one, two, or three 1.2 mm buccal FTA1
punches or a single 3.0 mm buccal FTA1 punch. Samples
containing one or two 1.2 mm punches reliably gave complete
proﬁles (alleles at all loci) (Fig. 1). With the punch number
increased to three 1.2 mm punches, an occasional failure was
observed. Reactions containing a single 3.0 mm punch size showed
minimal ampliﬁcation. Failures with three 1.2 mm punches and
one 3.0 mm punch are likely due to the increased amount of
inhibiting substances carried in the FTA1 paper overwhelming the
reaction.
3.2. FTA1 sample stability and performance
Stable long-term sample storage affords the opportunity for
retesting after several years. Five buccal FTA1 and ﬁve blood FTA1
samples were assayed to conﬁrm complete and accurate proﬁles
after storage on FTA1 for more than eight years. An additional ﬁve
blood FTA1 samples were tested which were stored as liquid blood
for approximately six years, then on FTA1 paper for two years
(eight years total). All samples gave full proﬁles which were
concordant with previous results at the loci included in the
PowerPlex1 16 System (Fig. 2).Fig. 2. Electropherograms from 8 year-old blood FTA1 sample (top), blood FTA1 sample f
analyzed on a 3130xl Genetic Analyzer with a 3 kV 5 s injection (n = 5).3.3. Reproducibility
Sample panels from two donors consisting of buccal FTA1
cards, blood FTA1 cards, and DNA extracts were distributed to ﬁve
independent laboratories. Expected genotypes were obtained from
all replicates of each sample type at each of the ﬁve independent
sites (Supplemental Fig. 3). Sample analysis performed with
multiple instruments, 3130, 3130xl, or 3500xL Genetic Analyzers,
and GeneMapper1 ID 3.2 and GeneMapper1 ID-X (Life Technolo-
gies/Applied Biosystems) analysis software versions gave match-
ing genotypes.
3.4. Accuracy
Commercially available PCR standards, Standard Reference
Material1 2391b PCR-based DNA Proﬁling Standards (NIST), were
evaluated to conﬁrm genotype accuracy. Extracted DNA samples 1
through 10 were ampliﬁed using 1 ng and 30 cycles or 5 ng and 27
and 28 cycles. Samples 11 and 12 arrived as cells on ﬁlter paper,
and were ampliﬁed both as extracted DNA (5 ng) and as a direct
ampliﬁcation (1.2 mm punch). Full concordance with the geno-
types listed in the Certiﬁcate of Analysis for Standard Reference
Material1 2391b was obtained for all samples at two independent
sites after analysis on 3130xl and 3500xL Genetic Analyzer
capillary electrophoresis platforms.
3.5. Precision
To demonstrate sizing precision, allelic ladder was run on
multiple capillary electrophoresis instruments across multiple
capillaries. Data from a total of 87 allelic ladder samples was
collected consisting of 15 samples on the 3130 Genetic Analyzer,
32 samples on the 3130xl Genetic Analyzer, 32 samples on the
3500xL Genetic Analyzer, and 8 samples on the 3730 DNA
Analyzer. Size variability was determined by calculating the
standard deviation for each allele on each instrument.
Very little variation was seen in the sizing and migration of the
allelic ladder at each locus across the capillary electrophoresis
instruments tested (Fig. 3, Supplemental Figs. 4–6). Three average
standard deviations were appreciably less than 0.2 bases for eachrom aged liquid blood (center), and 8 year-old buccal FTA1 (bottom). Samples were
Fig. 3. Sizing variation for all allelic ladder alleles on the 3130xl Genetic Analyzer using a 3 kV 5 s injection (n = 32). Similar plots for the 3130 and 3500xL Genetic Analyzers,
and 3730 DNA Analyzer can be viewed in Supplemental Figs. 2–4.
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Table 2). The 3730 DNA Analyzer produced more variation than the
other instruments. However, three average standard deviations
were less than 0.35 bases for each locus on this instrument.
Variation from all instruments was signiﬁcantly less than the 0.5
bases allowed by the allele-calling bin window provided in the
PowerPlex1 18D System bin ﬁle for GeneMapper1 ID 3.2 and ID-X
software. The median locus standard deviation was 0.036, 0.035,
0.042, and 0.065 bases on the 3130, 3130xl, 3500xl, and 3730
respectively. Not surprisingly, the highest locus variation seen was at
the largest loci, Penta D and Penta E.
3.6. Stutter
Because stutter peaks [7,8] can complicate interpretation, a
locus-speciﬁc stutter ﬁlter can be applied during analysis to
remove labels from stutter-position peaks with relative peak
intensities equal to or lower than those previously observed.
Stutter ﬁlter ratios were calculated by averaging ratios from 187
extracted DNA samples and 50 blood FTA1 samples at alleles with
peak heights less than 6000 RFU. The average stutter plus three
standard deviations (Table 2) was used as the stutter ﬁlter in the
PowerPlex1 18D Panel, Bins, and Stutter ﬁles for GeneMapper1 ID
3.2 and ID-X. The highest ratios (stutter peak height/allele peak
height) were seen at D3S1358, D21S11, and D2S1338 with none
greater than 8.8%. The loci with the lowest stutter ratios were
TH01, Penta D, and TPOX. Raw data for the stutter calculations can
be reviewed in greater detail in Supplemental Table 3.Table 2
Average stutter ratio (stutter peak height/allele peak height). The stutter ﬁlter has
been set as the average stutter ratio plus three standard deviations.
n= Average Mean + 3 std dev
D3S1358 195 0.088 0.13
TH01 77 0.023 0.04
D21S11 262 0.084 0.13
D18S51 271 0.072 0.13
Penta E 128 0.038 0.08
D5S818 111 0.074 0.13
D13S317 179 0.061 0.11
D7S820 126 0.051 0.11
D16S539 233 0.072 0.12
CSF1PO 197 0.058 0.10
Penta D 86 0.023 0.05
Amelo – – –
vWA 86 0.076 0.13
D8S1179 66 0.066 0.12
TPOX 93 0.035 0.07
FGA 209 0.071 0.12
D19S433 56 0.062 0.11
D2S1338 190 0.081 0.143.7. Allele frequency
The loci included in the PowerPlex1 18D System have been
tested extensively in previous multiplex products including the
PowerPlex1 16 System and the AmpF‘STR1 Identiﬁler1 PCR
Ampliﬁcation Kit. No additional population studies were per-
formed in the present developmental validation. Population
studies to determine allele frequencies have been published for
the CODIS core loci plus D2S1338 and D19S433 [9,10] along with
the CODIS core loci plus Penta D and Penta E [11,12]. Additionally, a
list of 365 global references on subsets of the 18 loci included in the
PowerPlex1 18D System is available [13].
3.8. Concordance
The design of the PowerPlex1 18D System conserves the proven
primer-binding sites from previously released Promega STR
systems, amelogenin, Penta D, Penta E, and the 13 CODIS loci
from the PowerPlex1 16 System and D2S1338 and D19S433 from
the PowerPlex1 ESI System. High conﬁdence was placed in the
PowerPlex1 18D System because of existing concordance data
[14,15]. Nevertheless, the new combination of loci and improved
master mix for direct ampliﬁcation warranted veriﬁcation.
Concordance was conﬁrmed by comparing a total of 418
PowerPlex1 18D genotypes generated from diverse sample
materials to proﬁles from existing, NDIS-approved multiplexes
including the PowerPlex1 16 System and the AmpF‘STR1
Identiﬁler1 PCR Ampliﬁcation Kit. The variety of sample types
included FTA1 (blood and buccal), S&S 903 (blood), Bode Buccal
DNA CollectorsTM, Omni SwabsTM, and extracted DNA. Direct
ampliﬁcations were performed using 1.2 mm disks punched from
FTA1 and S&S 903 added directly to reactions or 1.2 mm disks from
Bode Buccal DNA CollectorsTM pretreated with Bode PunchPrepTM.
Alternatively, reactions were performed using 2 ml of an Omni
SwabTM extract generated with prototype SwabSolutionTM (Pro-
mega) or 1 ml of extracted DNA. Proﬁles were generated on 3130
and 3130xl Genetic Analyzers as well as a 3730 DNA analyzer.
Of 418 full proﬁle samples, 415 samples were concordant with
prior laboratory results (Table 3). Three discordant calls were
detected in the 6688 loci compared (0.04%). In one individual, a
D2S1338 23, 23 genotype with the Identiﬁler1 Kit presented as a
17, 23 with the PowerPlex1 18D System. For a second individual,
the PowerPlex1 16 System produced a 12, 12 at CSF1PO, while the
PowerPlex1 18D System and the Identiﬁler1 Kit produced a 9, 12.
Sequencing performed on the D2S1338 and CSF1PO samples
uncovered single nucleotide mutations in both cases and
conﬁrmed the PowerPlex1 18D System genotype. In the case
where the PowerPlex1 16 System and the PowerPlex1 18D System
differed, formulation differences between the two systems and the
large template amount used with the PowerPlex1 18D System
Table 3
Number of full proﬁle samples compared for concordance across four independent laboratories using various collection and storage materials. NJSP, New Jersey State Police;
AZ DPS, Arizona Department of Public Safety; NIST, National Institute of Standards and Technology; TX DPS, Texas Department of Public Safety.
Sample NJSP AZ DPS NIST TX DPS Total System used for comparison:
Buccal FTA1 samples 47 47 Identiﬁler1 Direct
Bode Buccal DNA CollectorTM
(PunchPrepTM pretreatment)
77 77 Identiﬁler1
Blood FTA1 samples 50 50 Identiﬁler1 and PowerPlex1 16
Blood on S&S 903 paper 50 (Same donors as blood FTA1)
Extracted DNA 187 187 Identiﬁler1 and PowerPlex1 16
Omni SwabTM (prototype
SwabSolution pretreatment)
57 57 Identiﬁler1
418
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binding site mutation better than the PowerPlex1 16 System. A
third individual genotyped 13, 13 at D19S433 with the Identiﬁler1
Kit while the PowerPlex1 18D System generated a 13, 15 genotype.
Sequencing of the D19S433 discordant sample exposed a four-
nucleotide deletion ﬂanking an allele containing 16 repeats. The
PowerPlex1 18D System successfully ampliﬁed the allele, though
the allele was called as a 15 allele due to the four-nucleotide
deletion. All three discordant calls were due to a null allele in the
system used for comparison, not with the PowerPlex1 18D System.
3.9. Cycle number
Direct ampliﬁcation samples, either on storage cards or swabs,
contain variable amounts of material due to donor shedding levels,
collection techniques, and sample type. This variability can be
observed directly in STR analysis as a wide range of sample signal
strengths within a typical sample. To improve rerun rates due to
signal strength, cycle number optimization can identify conditions
which either ﬁt common sample intensities or allow detection of
the weakest samples. The cycle number evaluation included
ampliﬁcations at 25, 27, 30, and 32 cycles using two donors each
for blood FTA1 samples, buccal FTA1 samples, and extracted DNA
(1 and 5 ng). The technical manual recommends using 27 cycles
with 5 ng of DNA. As expected, peak heights rose with increasing
cycle number (Fig. 4). Full proﬁles were reliably seen with buccal
FTA1, blood FTA1, and 5 ng of extracted DNA with 27 cycles or
more. At 30 or more cycles buccal and blood FTA1 samples gave
several off-scale peaks. Injection conditions may also be altered to
increase or decrease signal strength.
3.10. Final extension
A ﬁnal 60 8C extension step in PCR is known to improve
adenylation of the ampliﬁed fragments [16,17]. Without the
ﬁnal extension step fragments would often have n  1 peaksFig. 4. Average peak heights with increasing cy(minus A) or shoulders, which can complicate data interpreta-
tion. Excess-template samples common with direct ampliﬁca-
tion can also affect adenylation. A ﬁnal extension study included
a ﬁnal extension step of 0, 10, or 20 min at 60 8C using blood
FTA1 samples, buccal FTA1 samples, and 5 ng of extracted
2800 M Control DNA. Minus A shoulders and peaks were
manually counted. Blood FTA1 samples yielded the most minus
A, followed by buccal FTA1 and extracted DNA sample types. A
ﬁnal extension step of 10 min removed the majority of the
minus A peaks. Increasing the ﬁnal extension from 0 to 10 min
reduced minus A from 17% to 4% in blood FTA1 samples
(Supplemental Fig. 7). Lengthening the extension step to 20 min
was not detrimental to the results, and could further reduce
minus A peaks in heavy samples or with lower quality PCR
plates.
3.11. Annealing temperature
Large deviations from the recommended annealing tempera-
ture have the potential to alter the performance of an STR
system. The optimal annealing temperature was evaluated by
testing FTA1 sample and extracted DNA (5 ng) ampliﬁcations
with annealing temperatures 2 8C and 4 8C from the recom-
mended annealing temperature of 60 8C (56 8C, 58 8C, 60 8C, 62 8C
and 64 8C). No allelic dropout was seen for all sample types at
temperatures from 56 8C to 64 8C (Supplemental Fig. 8). The
optimal annealing temperature of 60 8C was veriﬁed since artifacts
appeared at 56 8C and peak heights decreased at particular loci at
64 8C. At an annealing temperature of 56 8C observed artifacts
included: 119, 127, 198, 237, 275, 277, 346, 354, and 405 bases in
FAM, 129 and 349 bases in JOE, and 135 bases in ET-CXR. Artifacts
were generally higher with extracted DNA than buccal FTA1. At
64 8C reduced peak heights were observed at amelogenin,
D8S1179, and D2S1338. Though optimal results are seen at the
recommended annealing temperature, the PowerPlex1 18D System
was tolerant to some annealing temperature variation.cle numbers across multiple sample types.
Table 4
Highest concentrations of PCR inhibitor where full proﬁles were observed with both replicates. All concentrations were ﬁnal concentrations in the 25 ml reaction (n = 2, EDTA
n = 3) NA = not tested.
Hematin Humic Tannic EDTA Ethanol SDS
DNA 800 mM 200 ng/ml >500 ng/ml 0.5 mM 8% 0.8 mg/ml
Buccal 2 punches 500 mM 150 ng/ml 150 ng/ml 1.0 mM 2.5% 0.4 mg/ml
Blood 1 punch NA NA NA 0.5 mM NA NA
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Direct ampliﬁcation materials are typically cruder than puriﬁed
samples and often include inhibitors from FTA1 paper or whole
blood. Adding the same amount of direct ampliﬁcation material
recommended for a full reaction into a reduced reaction volume can
negatively impact performance. Reduced reaction volumes were
tested using one or two punches buccal FTA1 sample, blood FTA1
sample, and 5 ng of extracted DNA at 25 ml, 18.75 ml, 12.5 ml, and
6.25 ml reaction volumes. Examination showed reaction volumes
12.5 ml produced reliable full proﬁles with one punch buccal FTA1
sample (Supplemental Fig. 9), one punch blood FTA1 sample, or DNA
from 1 to 5 ng. Two punches of buccal FTA1 sample with reaction
volumes less than 25 ml demonstrated variable success. Reliable
performance from reduced reaction volume is achievable; however
adjustments in sample input may be necessary.
3.13. Reaction components
Primer, DNA polymerase, and magnesium concentrations in
large multiplex systems are essential [18,19] and highly optimized
for consistent and robust results. Component concentrations 25%
from the manufactured formulation were evaluated using multiple
sample types, including two donors each for buccal FTA1 samples,
blood FTA1 samples, and extracted DNA (5 ng). The PowerPlex1 18D
System was sufﬁciently robust to handle component concentration
changes 25% above or below the recommended concentrations with
minor impact on results with all the sample types evaluated. Full
proﬁles were seen at all primer, DNA polymerase, and magnesium
concentrations. Further, a corresponding 25% change in peak heights
was seen with changing primer concentrations (Supplemental Fig.
10). With altered magnesium concentrations, an equivalent 20–25%
change in peak heights was observed (Supplemental Fig. 11). Changes
in polymerase concentration, however, produced little change in peak
height (Supplemental Fig. 12).
3.14. Species speciﬁcity
Although the PowerPlex1 18D System is intended for human
single source samples, biological materials from other species may
contaminate samples. Microorganism species cross-reactivity is
especially relevant since typical samples originate from microbe-
rich environments such as the oral cavity. Microbial as well as
primate and domestic animal DNAs were characterized using 30
cycles, three more cycles than recommended for a typical sample.
One nanogram was tested for primates and bacteria, 10 ng for
domestic animals, and 2 ng for yeast. The primate species DNA
yielded many peaks both on and off-ladder, similar to results with
other STR multiplexes. Multiple off ladder peaks distinguish the
resulting proﬁle from a human proﬁle (Supplemental Fig. 13).
Sporadic peaks were observed with domestic animal DNA.
Prominent peaks included 107 bp in TMR for cow, horse, dog,
pig, and deer (horse, dog, pig, and deer not shown), 440 bp in JOE
(atypical peak shape) for chicken, and 111 bp in FAM for rabbit. The
microorganisms gave minimal cross reactivity. The only detectable
peaks were 440 bp in JOE for E. coli, and 134 bp and 387 bp in JOE
for A. lwofﬁi.3.15. Inhibiting substances
With a system capable of direct ampliﬁcation from unwashed
FTA1 punches, the selection of usable samples widens signiﬁcantly
to encompass simple cell lysates and FTA1 punches as well as
puriﬁed DNA. A diverse collection of PCR-inhibiting substances at
high concentrations may be encountered with unpuriﬁed or poorly
puriﬁed samples originating from either the sample or the
puriﬁcation method. Several common forensic inhibitors were
titrated into reactions to assess tolerance to multiple contaminat-
ing compounds. The evaluation included environmental sub-
stances such as hematin [20], humic acid [21], tannic acid [21],
chocolate, tobacco and coffee, as well as substances from typical
puriﬁcation methods including EDTA [22], ethanol [22], and SDS
[23]. All concentrations listed were ﬁnal reaction concentrations.
Inhibitor concentration ranges included 0–1 mM hematin, 0–
350 ng/ml humic acid, and 0–500 ng/ml tannic acid. Concentra-
tions of EDTA at 0–1 mM, ethanol at 0–12%, and SDS at 0–1 mg/ml
were evaluated as well. Inhibitor titrations were performed using
both buccal FTA1 and 5 ng of extracted DNA. EDTA testing
additionally included blood FTA1 samples. Lastly, chocolate, sugar,
tobacco, and coffee (10 ml) evaluations were performed singly with
buccal FTA1 reactions.
The PowerPlex1 18D System tolerated a broad range of
inhibitors, giving full proﬁles with both extracted DNA and buccal
FTA1 samples at substantial inhibitor concentrations (Table 4). For
all inhibitors, peak heights dropped with increasing concentrations
of inhibitor (Supplemental Figs. 14–19). Typically, the largest loci
were the ﬁrst to drop out. Extracted DNA generally showed higher
tolerance to inhibiting substances than FTA1 samples. More
speciﬁcally, full proﬁles were generated with hematin concentra-
tions 800 mM using 5 ng of extracted DNA and 500 mM using
buccal FTA1 samples (Supplemental Fig. 20). With humic acid, full
proﬁles were seen with 200 ng/ml using 5 ng of extracted DNA
and 150 ng/ml using buccal FTA1. Tannic acid inhibited buccal
FTA1 reactions at lower concentrations than with extracted DNA,
150 ng/ml and >500 ng/ml respectively. Large amounts of
chocolate and tobacco were severely inhibiting. However, lower
amounts of tobacco were overcome. Coffee and sugar allowed full
proﬁles to be collected but with reduced overall peak heights
(Supplemental Fig. 21).
The PowerPlex1 18D System tolerated considerable concentra-
tions of puriﬁcation-related inhibitors as well. Full proﬁles were
observed with 1 mM EDTA with buccal FTA1 samples and
0.5 mM EDTA with blood FTA1 samples and 5 ng of extracted
DNA. Ethanol contamination of 8% generated full proﬁles with
5 ng of extracted DNA. Buccal FTA1 samples gave full proﬁles with
2.5% ethanol. Contamination with SDS was tolerated at 0.8 mg/
ml with 5 ng of extracted DNA and 0.4 mg/ml with buccal FTA1
samples.
4. Conclusion
Direct ampliﬁcation with STR multiplex systems presents
opportunities for process simpliﬁcation. However, inherent varia-
tion brings new challenges and considerations for optimization.
Although direct ampliﬁcation offers the beneﬁts of faster and
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or pristine. Sample distribution across the material varies, as does
the amount of material collected. When sampling the sample
distribution and density variability can compound, and therefore,
larger peak height variations can be observed sample-to-sample
compared with extracted DNA samples. Additionally, typical
samples are crude introducing various combinations and levels
of PCR inhibitors directly into a reaction. Reagent improvements
made with the PowerPlex1 18D System have been speciﬁcally
targeted to address direct ampliﬁcation challenges, and quality
genotypes can be obtained with signiﬁcantly less labor and
resources than previously. Nonetheless, optimization of individual
laboratory conditions and processes is recommended.
SWGDAM and NDIS requirements have been established to
ensure new STR multiplexes are sufﬁciently robust and reliable for
human identiﬁcation purposes. The data reported demonstrates
the PowerPlex1 18D System produces high quality data that can be
reliably generated under sub-optimal conditions and challenging
samples. The PowerPlex1 18D System has been shown to be
sensitive to low amounts of DNA, robust in handling changes in
component concentrations, annealing temperature and PCR
inhibitors, and is sufﬁciently precise to make accurate genotype
calls. Most importantly, multiple laboratories found concordance
with existing STR multiplexes and high full-proﬁle success rates
with their current laboratory samples, covering a wide variety of
materials. Given these results, the PowerPlex1 18D System can
conﬁdently be used for forensic and identiﬁcation testing.
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